Vamorolone (AGAMREE)
Duchenne Muscular Dystrophy (DMD)
ApprovedActive
Key Facts
About ReveraGen BioPharma
ReveraGen BioPharma is a pioneering biotech that has successfully developed and gained regulatory approval for vamorolone, a first-in-class dissociative steroid for Duchenne muscular dystrophy. The company achieved this milestone through an innovative venture philanthropy and public-private partnership model, operating with an exceptionally lean team. Its focus remains on leveraging its steroid chemistry expertise to create safer anti-inflammatory treatments for rare diseases with high unmet need.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (DMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DT-DEC01 | Dystrogen Therapeutics | Phase 1 |
| Skeletal Muscle Regeneration Program | IPS HEART | Pre-clinical |
| KYMBEE (deflazacort) | Upsher-Smith | Approved |
| ALY688ER | Allysta Pharmaceuticals | Phase 1 |
| AVGN7 + AVGND | AAVogen | Pre-clinical |
| Myomatrix Stabilization Program | Strykagen | Preclinical |
| RIPPLE™ (implied) | SonoThera | Preclinical |
| RGX-202 | ReGenX Biosciences | Phase 1/2 |
| AGAMREE (vamorolone) | Catalyst Pharmaceuticals | Marketed |
| EDG-5506 | Edgewise Therapeutics | Phase 2 |
| ELEVIDYS (delandistrogene moxeparvovec-rokl) | Sarepta Therapeutics | Marketed / Phase 3 |
| SRP-5051 (vesleteplirsen) | Sarepta Therapeutics | Phase 2 |